Frontiers in Immunology (Oct 2024)
Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors
- Marcelo Hurtado,
- Leila Khajavi,
- Abdelmounim Essabbar,
- Michael Kammer,
- Michael Kammer,
- Ting Xie,
- Alexis Coullomb,
- Anne Pradines,
- Anne Pradines,
- Anne Casanova,
- Anne Casanova,
- Anna Kruczynski,
- Sandrine Gouin,
- Estelle Clermont,
- Estelle Clermont,
- Léa Boutillet,
- Maria Fernanda Senosain,
- Maria Fernanda Senosain,
- Yong Zou,
- Yong Zou,
- Shillin Zhao,
- Prosper Burq,
- Abderrahim Mahfoudi,
- Jerome Besse,
- Pierre Launay,
- Alexandre Passioukov,
- Eric Chetaille,
- Gilles Favre,
- Fabien Maldonado,
- Francisco Cruzalegui,
- Olivier Delfour,
- Julien Mazières,
- Julien Mazières,
- Vera Pancaldi,
- Vera Pancaldi
Affiliations
- Marcelo Hurtado
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Leila Khajavi
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Abdelmounim Essabbar
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Michael Kammer
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Michael Kammer
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
- Ting Xie
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Alexis Coullomb
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Anne Pradines
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Anne Pradines
- Laboratory Medicine, Oncopole Claudius Regaud, Toulouse, France
- Anne Casanova
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Anne Casanova
- Laboratory Medicine, Oncopole Claudius Regaud, Toulouse, France
- Anna Kruczynski
- Institut de Recherche Pierre Fabre, Toulouse, France
- Sandrine Gouin
- Pulmonology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France
- Estelle Clermont
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Estelle Clermont
- Laboratory Medicine, Oncopole Claudius Regaud, Toulouse, France
- Léa Boutillet
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Maria Fernanda Senosain
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
- Maria Fernanda Senosain
- Cancer Early Detection and Prevention Initiative, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical. Center, Nashville, TN, United States
- Yong Zou
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
- Yong Zou
- Cancer Early Detection and Prevention Initiative, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical. Center, Nashville, TN, United States
- Shillin Zhao
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States
- Prosper Burq
- Data Science, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- Abderrahim Mahfoudi
- Institut de Recherche Pierre Fabre, Toulouse, France
- Jerome Besse
- Institut de Recherche Pierre Fabre, Toulouse, France
- Pierre Launay
- Institut de Recherche Pierre Fabre, Toulouse, France
- Alexandre Passioukov
- Institut de Recherche Pierre Fabre, Toulouse, France
- Eric Chetaille
- Institut de Recherche Pierre Fabre, Toulouse, France
- Gilles Favre
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Fabien Maldonado
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
- Francisco Cruzalegui
- Institut de Recherche Pierre Fabre, Toulouse, France
- Olivier Delfour
- Institut de Recherche Pierre Fabre, Toulouse, France
- Julien Mazières
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Julien Mazières
- Pulmonology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France
- Vera Pancaldi
- CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France
- Vera Pancaldi
- 0Life Sciences Department, Barcelona Supercomputing Center, Barcelona, Spain
- DOI
- https://doi.org/10.3389/fimmu.2024.1394965
- Journal volume & issue
-
Vol. 15
Abstract
BackgroundLung cancer is the leading cause of cancer death worldwide, with poor survival despite recent therapeutic advances. A better understanding of the complexity of the tumor microenvironment is needed to improve patients’ outcome.MethodsWe applied a computational immunology approach (involving immune cell proportion estimation by deconvolution, transcription factor activity inference, pathways and immune scores estimations) in order to characterize bulk transcriptomics of 62 primary lung adenocarcinoma (LUAD) samples from patients across disease stages. Focusing specifically on early stage samples, we validated our findings using an independent LUAD cohort with 70 bulk RNAseq and 15 scRNAseq datasets and on TCGA datasets.ResultsThrough our methodology and feature integration pipeline, we identified groups of immune cells related to disease stage as well as potential immune response or evasion and survival. More specifically, we reported a duality in the behavior of immune cells, notably natural killer (NK) cells, which was shown to be associated with survival and could be relevant for immune response or evasion. These distinct NK cell populations were further characterized using scRNAseq data, showing potential differences in their cytotoxic activity.ConclusionThe dual profile of several immune cells, most notably T-cell populations, have been discussed in the context of diseases such as cancer. Here, we report the duality of NK cells which should be taken into account in conjunction with other immune cell populations and behaviors in predicting prognosis, immune response or evasion.
Keywords
- lung adenocarcinoma
- natural killer cells
- immune landscape
- cell deconvolution
- transcription factor activity